Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Johnson & Johnson is transforming solid tumor cancer outcomes with new findings on RYBREVANT® and TAR-200
Johnson & Johnson presents new findings on RYBREVANT® for lung and colorectal cancers, TAR-200 for bladder cancer at WCLC and ESMO 2024. Highlights include RYBREVANT®'s efficacy in EGFR-mutated NSCLC and its potential in metastatic colorectal cancer, alongside TAR-200's organ-sparing therapy for bladder cancer.
Johnson & Johnson is transforming solid tumor cancer outcomes with new treatments
Johnson & Johnson presents new findings on RYBREVANT® for lung and colorectal cancers, TAR-200 for bladder cancer, and other treatments at WCLC and ESMO 2024. Highlights include RYBREVANT®'s efficacy in EGFR-mutated NSCLC and its potential in metastatic colorectal cancer, alongside TAR-200's organ-sparing therapy for bladder cancer.
FDA Approves Rybrevant (amivantamab-vmjw) Plus Lazcluze (lazertinib) for Patients with EGFR-Mutated Advanced Lung Cancer
FDA approves Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for first-line treatment of EGFR-mutated advanced NSCLC, marking a significant development for patients with unmet needs.
Related Clinical Trials:
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib): A Chemotherapy-Free Regimen for EGFR-Mutated NSCLC
RYBREVANT® plus LAZCLUZE™, approved by the FDA, is the first chemotherapy-free regimen for EGFR-mutated NSCLC, showing a 30% reduced risk of disease progression or death versus osimertinib, with a nine-month longer median duration of response. This marks a significant advancement in NSCLC treatment.
Related Clinical Trials:
J&J drug combo for lung cancer approved by FDA
FDA approved Johnson & Johnson's Rybrevant with Lazcluze for untreated, advanced non-small cell lung cancer with specific EGFR mutations. This chemotherapy-free regimen showed a 30% lower risk of cancer progression or death compared to AstraZeneca's Tagrisso, despite higher side effects. Patients require prophylactic anticoagulation due to safety concerns.
Cilta-Cel for Functional High-Risk Myeloma
Dr. Luciano Costa discussed the CARTITUDE-4 trial at ASCO 2024, highlighting cilta-cel's efficacy for functional high-risk myeloma patients. Cilta-cel showed superior response rates and progression-free survival compared to standard care, with manageable side effects, suggesting it as a viable treatment option.
Artificial Intelligence (AI) in Healthcare Market Size
The global AI in healthcare market is projected to grow from USD 19.27 billion in 2023 to USD 613.81 billion by 2034, driven by technological advancements and government initiatives. North America leads with a 45% market share in 2023. AI enhances diagnostics, personalized medicine, and administrative efficiency, with significant growth expected in the Asia-Pacific region.
Brazil Cancer Drugs Market Clinical Trials Report 2024: Brazil Emerges as a Leading Force in Cancer Drug Clinical Trials
Brazil emerges as a key hub for oncology clinical trials, with Roche leading in trials for drugs like Atezolizumab and Pertuzumab. The country focuses on prevalent cancers, with NSCLC trials dominating. Phase III trials are prevalent, supported by CROs, indicating Brazil's role in global cancer research.
Sanofi’s Sarclisa wins in transplant-eligible multiple myeloma trial
Sanofi’s Sarclisa, combined with standard care, significantly improves progression-free survival in newly diagnosed multiple myeloma patients eligible for stem cell transplant, as shown in a Phase III trial. It targets CD38, leading to cell death and immune-mediated destruction. Sarclisa, already approved for relapsed refractory multiple myeloma, aims for earlier treatment settings, competing with Johnson & Johnson’s Darzalex.
© Copyright 2025. All Rights Reserved by MedPath